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Email
g.dimitriadis@warwick.ac.ukSummaryWe report the case of a 70-year-old previously healthy female who presented acutely to the Accident and Emergency
department with left-sided vasomotor symptoms including reduced muscle tone, weakness upon walking and slurred
speech. Physical examination confirmed hemiparesis with VIIth nerve palsy and profound hepatomegaly. A random glucose
was low at 1.7 mmol/l, which upon correction resolved her symptoms. In hindsight, the patient recalled having had similar
episodes periodically over the past 3 months to which she did not give much attention. While hospitalized, she continued
having episodes of symptomatic hypoglycaemia during most nights, requiring treatment with i.v. dextrose and/or glucagon.
Blood tests including insulin and C-peptide were invariably suppressed, in correlation with low glucose. A Synacthen
stimulation test was normal (Cort (0 0) 390 nmol/l, Cort (30 0) 773 nmol/l). A computed tomography scan showed multiple
lobulated masses in the abdomen, liver and pelvis. An ultrasound guided biopsy of one of the pelvic masses was performed.
Immunohistochemistry supported the diagnosis of a gastrointestinal stromal tumour (GIST) positive for CD34 and CD117.
A diagnosis of a non islet cell tumour hypoglycaemia (NICTH) secondary to an IGF2 secreting GISTwas confirmed with further
biochemical investigations (IGF2Z96.5 nmol/l; IGF2:IGF1 ratio 18.9, ULN !10). Treatment with growth hormone resolved
the patient’s hypoglycaemic symptoms and subsequent targeted therapy with Imatinib was successful in controlling disease
progression over an 8-year observation period.Learning points:
† NICTH can be a rare complication of GISTs that may manifest with severe hypoglycaemia and neuroglucopenic
symptoms.
† NICTH can masquerade as other pathologies thus causing diagnostic confusion.
† Histological confirmation of GIST induced NICTH and exclusion of other conditions causing hypoglycaemia
is essential.
† Mutational analysis of GISTs should be carried out in all cases as it guides treatment decision.
† Tailored management of hypoglycaemia, in this case using growth hormone and targeted cyto-reductive therapy,
minimizes the risk of possible life-threatening complications.http://www.edmcasereports.com
Published by Bioscientifica Ltd
Table 1 Initial evaluation for sources of hypoglycemia.
Investigations
Patient’s
serum Reference range
Glucose 1.7 mmol/l 4.0–5.9 mmol/l
Insulin !10 pmol/l !174 pmol/l (fasting)
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Gastrointestinal stromal tumours (GISTs) are defined as
morphologically spindle cell, epithelioid, or occasionally
pleomorphic mesenchymal tumours of the gastrointes-
tinal tract. In Caucasian populations, their annual
incidence is 10–15 cases per million and they are evenly
distributed between genders. GIST usually express receptor
tyrosine kinase KIT protein and harbour mutation of a
gene that encodes for a type III receptor tyrosine kinase
(either KIT or platelet-derived growth factor receptor A
(PDGFRA)). Approximately 80% of GISTs harbour KIT and
5% PDGFRA mutations and w90% are CD-117 positive.
The ligand for the receptor is a stem-cell factor, which is
essential for development and proliferation of a variety of
cell types.
GISTs often grow asymptomatically until they are
discovered due to the appearance of signs and symptoms
related to mass pressure effects, bleeding or bowel per-
foration. Tumour related hypoglycaemia is rare and most
frequently occurs in insulinomas but can also occasionally
occur in non-islet cell tumours. Non islet cell tumour
hypoglycemia (NICTH) is observed in some epithelial and
mesenchymal tumours and rarely also in GISTs.
NICTH is characterised by recurrent fasting hypogly-
caemia and associated with the secretion of incompletely
processed precursors of insulin-like growth factor (IGF) 2
by the tumour into the circulation. These precursors
consist mainly of mature IGF2 with a 21-residue carboxyl
extension of the E-domain of pro-IGF2 called pro-IGF2E or
‘big’-IGF2 (1).
In this report, we present a rare case of severe NICTH
due to overproduction of Insulin Growth Factor 2 (IGF2)
secondary to a GIST. The importance of our case is that it
raises awareness among healthcare professionals of NICTH
as a rare complication of ectopic overproduction of IGF2
in patients with GISTs. This case points out challenges
associated with its diagnosis and the importance of
symptom control and prompt disease control with either
surgery, targeted therapy or combined treatment based
on staging.
C-peptide 99 pmol/l 170–900 pmol/l (fasting)
Cortisol 532 mmol/l 190–720 mmol/l (0900 h)
Chlorpropamide 0 mg/ml 0 mg/ml
Tolazamide 0 mg/ml 0 mg/ml
Tolbutamine 0 mg/ml 0 mg/ml
Acetohexamide 0 mg/ml 0 mg/ml
Glipizide 0 mg/ml 0 mg/ml
Gliclazide 0 mg/ml 0 mg/ml
IGF1 5.1 nmol/l 6–36 nmol/l
IGF2 96.5 nmol/l
IGF2/1 ratio 18.9 !10
Betahydroxybutyrate 330 mmol/lCase presentation
In July 2007, a 70-year-old Caucasian retired female
presented to the accident and emergency department
with headache and left-sided vasomotor symptoms
including reduced muscle tone, weakness and slurring of
speech upon walking. Further discussion revealed that
she had been suffering from similar symptoms of varyinghttp://www.edmcasereports.comseverity over the past year but that for 3 months the
symptoms had been increasing in frequency and severity.
She thought they were migraines and treated them
unsuccessfully with paracetamol.
She had no significant previous medical history, was
on no medication at the time of presentation and did not
report any known allergies. Physical examination of the
neurological system confirmed left hemiparesis with
paresthesia and VIIth cranial nerve palsy with unilateral
facial weakness and ptosis which rose initial suspicions of
underlying vascular central nervous system (CNS) path-
ology. Abdominal examination revealed a heterogenous,
hard and enlarged but painless liver. Observations
included BP: 155/85 mmHg, HR: 115 bpm, T: 36.8 8C and
RR: 19/min. There were no other significant findings on
examination.Investigation
Initial A&E assessment, revealed a low non-fasting venous
glucose consentration of 1.7 mmol/l (30.1 mg/dl) whilst
further routine biochemistry markers were normal.
Previous blood glucose levels as performed by the
patient’s GP a few months earlier were unremarkable
(FBG: 4.7 mmol/l – 09/2006). The patient was not over-
weight (BMI: 23 kg/m2) There was no family history of
impaired glucose control. The patient was admitted for
symptom control and further diagnostics.
During her inpatient stay, she developed frequent
hypoglycaemias especially at night that required treatment
with i.v. administration of dextrose and/or glucagon.
Further endocrine investigations (Table 1) for insulin,
C-peptide and baseline cortisol (532 mmol/l) were
requested and a Synacthen test was performed which2
AB
Figure 1
Dual phase, contrast enhanced abdominal (A) and liver (B) CT scans
pre-imatinib mesylate treatment. Marked with arrows is the impressive
long term disease response (27/07/2007).
A
B
C
Figure 2
(A) and (B) Immunohistochemical study showing tumour cells positive for
proto-oncogene c-kit (CD 117) and DOG-1. (C) Light microscopy showing
hypercellular spindle cells arranged in fascicles and whorls.
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cort (0 0) 390 nmol/l, (30 0) 773 nmol/l).
A dual phase contrast enhanced CT scan revealed
multiple lobulated masses in the abdomen and pelvis. The
two largest lobulated masses were located in the pelvis,
measuring 14!8 cm in the axial plane, extending into the
lower abdomen; and another in the suprapubic region
measuring 9!11 cm. Each of these pelvic masses showed
uneven enhancement, with areas of low density, either
cystic or necrotic. There was another large, lobulated
omental mass with similar characteristics, and multiple
peritoneal and mesenteric masses of varying sizes. In
addition, there were multiple poorly defined low density
lesions scattered throughout the liver in keeping with
secondary deposits (Fig. 1A and B).
An ultrasound guided biopsy of the largest pelvic
mass (14!8 cm) was performed. Histological analysishttp://www.edmcasereports.comconfirmed the diagnosis of a GIST, strongly positive for
proto-oncogene c-KIT CD117 and CD34 (Fig. 2A and B).
Disease extent based on TNM staging was pT4N1M1 G3
(Stage IV). Based on international and national guidelines3
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and PDGFR variations.
The diagnosis of an NICTH secondary to an IGF2
secreting GIST was further confirmed biochemically (IGF2
96.5 nmol/l; IGF2:IGF1 ratio 18.9 (reference ratio !10)).
Insulin and C Peptide levels were invariably suppressed in
correlation with the profound hypoglycaemia at the time
of analysis.B
Figure 3
Dual phase, contrast enhanced abdominal (A) and liver (B) CT scans post-
imatinib mesylate treatment. Marked with arrows is the impressive long
term disease response (15/02/2015).Treatment
Prior to availability of the histopathology results,
treatment with diazoxide (5 mg/kg per day given 8 hourly)
was provided for 5 days but failed to control her
hypoglycaemic episodes as can be anticipated in sub-
sequently confirmed NICTH, given that NICTH related
hypoglycemia is not responsive to K-ATP channel
activity (3).
Prednisolone 20 mg once daily in the morning was
started 7 days after initial presentation and adequately
controlled her symptoms allowing weaning from i.v.
glucose (4) (5). To minimise steroid induced side effects,
treatment with recombinant human growth hormone was
added (4) (5) (6), which allowed tapering down the dose of
prednisolone.
Further treatment options for GISTs include surgery or
targeted cyto-reductive therapy with highly specific
Imatinib mesylate, especially in the adjuvant setting and
metastatic diseasewith focus on tumour burden reduction.
Mutational analyses indicated the presence of the
common KIT exon 11 mutation. At this point, following
MDT discussion targeted therapy with selective anti-
PDGFRa and anti-KIT tyrosine kinase inhibitor (TKI)
Imatinib mesylate was deemed as the most suitable
treatment option due to the extensive disease. Treatment
with the lowest 400 mg/day Imatinib mesylate dose was
initiated based on the results of the mutational analysis
and existing guidelines for the common KIT exon 11
mutation response to Imatinib mesylate.Outcome and follow-up
Treatment with Imatinib mesylate caused rapid neuroglu-
copenic symptom control and allowed for further tapering
of the steroid dose until discontinuation in August 2007.
Therapy with human recombinant growth hormone was
also discontinued as the patient stopped having hypo-
glycaemias within weeks after first receiving Imatinib
mesylate.http://www.edmcasereports.comTumour burden was dramatically reduced and
long term partial response was achieved (O30%
tumour load shrinkage) without any signs of tumour
dedifferentiation or development of gradual resistance to
therapy even after 8 years following the diagnosis
(Fig. 3A and B).
The patient today aged 78 years old still continues to
do well on the preceding treatment and at present does
not experience any hypoglycaemic episodes or related
symptoms. Nevertheless, she still continues to monitor
her glucose levels and has IM glucagon and support
in the case of an emergency.Discussion
The incidence of NICTH ranges from 2.1 to 15 per million
people and is evenly distributed between genders (7) (8).4
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parenchymal tumours, but may rarely also present in
other types of cancer such as advanced adenocarcinomas
of the colon (4) (9).
Searching PubMed for ‘GIST’ and ‘hypoglycaemia’
only reveals 10 previous reports. In four of the cases
expression of ‘big’ IGF2 was reported and in two cases
there was over expression of pro-IGF2 (10) (11). High
concentrations of pre-pro-IGF2 genes that are not properly
glycosylated result in the high molecular weight ‘big’
IGF2. Compared to physiologic IGF2, it has a significantly
higher affinity to the insulin receptor, and a lower affinity
to its binding protein (IGFBP-3) (1). The association of
‘big’ IGF2 and NICTH was first reported by Daughaday
et al. in a patient with a fibrosarcoma (9). Non islet cell
tumour-induced hypoglycemia secondary to ‘big’ IGF2 is
difficult to confirm because routine diagnostic tests are not
widely available.
Hence, an easier accessible pathognomic biochemical
feature can be an IGF2:IGF1 ratio of R10 as well as low
insulin, c-peptide and growth hormone concentrations.
However, the exact mechanisms of GIST induced hypo-
glycaemia are incompletely identified. Possible expla-
nations include impaired glucose metabolism or
decreased hepatic gluconeogenesis. In addition, given
that clinically detectable hypoglycaemia appears to be
associated with high tumour burden, auto-paracrine
IGF2-mediated increased glucose metabolism may contri-
bute in explaining hypoglycaemia in GISTs (12).
Optimal management of NICTH includes hypoglycae-
mia symptom control, surgical removal of the primary
tumour if amenable to surgical resection, thereby target-
ing the source of IGF2 excess ectopic production.
However, in extensively disseminated disease, as was the
case of our patient, targeted medical treatment appears
to be an effective alternative option for the treatment of
GIST induced NICTH.
Mutational analysis in GIST is crucial as it identifies
less sensitive or resistant genotypes (PDGFR D842V) who
may not benefit from therapy with the selective TKI
Imatinib mesylate and allows dose adjustment for patients
with KIT exon 9 mutations (800 mg/day) whereas the
standard dose in the most common KIT exon 11 mutation
is 400 mg/day.
For the treatment of severe hypoglycaemic episodes,
various pharmacological treatments are available. Diaz-
oxide is often tried but is usually ineffective as its effect is
through normal K-ATP channels. Steroids and growth
hormone represent an alternative palliative strategy for
short-term management of symptomatic hypoglycaemia.http://www.edmcasereports.comTreatment with Imatinib appears to be another effective
option but is expensive and not always successful at
managing symptoms of hypoglycaemia. Surgical resection
remains the most rapid and cost-effective therapy to
normalize glucose metabolism in most cases of NICTH
and should be the preferable option when indicated.
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